FDA Approves Diagnostic Imaging Agent Axumin for Recurrent Prostate Cancer

FDA Approves Diagnostic Imaging Agent Axumin for Recurrent Prostate Cancer
The US Food and Drug Administration (FDA) has recently approved Axumin, an injectable radioactive diagnostic agent used to detect recurrent prostate cancer. Axumin (marketed by Blue Earth Diagnostics, Ltd., Oxford, United Kingdom) is indicated for positron emission tomography (PET) imaging in patients previously treated but who are suspected to have recurrent disease based on elevated levels

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *